BioSpace News Archive

What percentage of a population needs to be immune in order to achieve herd immunity is a matter of debate among scientists and public health officials.

Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.

This approval marks the first treatment indicated for reducing mortality risk in patients with the rare disorder known as molybdenum cofactor deficiency (MoCD) Type A.

On Sunday, Reuters reported the U.K. pharma giant sold off its 7.7% stake in the company for more than $1 billion.

Merck KGaA, Darmstadt, Germany plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.

Suzhou Medilink Therapeutics (Medilink), based in Suzhou, China, closed on a $50 million Series A financing round. An A1 series round was led by Apricot Capital and a series-A1 was co-led by Loyal Valley Capital and Qiming Venture Partners.

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors .

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (the “Company”) a medical technology company in dermatology and plastic surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that, as previously reported on its Form 8-K filed on March 1, 2021, effective as of the close of trading on March 1, 2021,

SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the first quarter of fiscal year 2021, ended December 31, 2020

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share